Business Description
Tempest Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US87978U1088
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.9 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.77 | |||||
Debt-to-EBITDA | -0.75 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.2 | |||||
3-Year EPS without NRI Growth Rate | 12.9 | |||||
3-Year FCF Growth Rate | 14.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.81 | |||||
9-Day RSI | 49.4 | |||||
14-Day RSI | 47.75 | |||||
6-1 Month Momentum % | -12.71 | |||||
12-1 Month Momentum % | 106.11 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.29 | |||||
Quick Ratio | 4.29 | |||||
Cash Ratio | 4.17 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.2 | |||||
Shareholder Yield % | -49.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -247.13 | |||||
ROA % | -77.71 | |||||
ROIC % | -175.57 | |||||
ROC (Joel Greenblatt) % | -238.29 | |||||
ROCE % | -93.79 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.93 | |||||
Price-to-Tangible-Book | 2.93 | |||||
EV-to-EBIT | -2.09 | |||||
EV-to-Forward-EBIT | -1.65 | |||||
EV-to-EBITDA | -2.12 | |||||
EV-to-Forward-EBITDA | -1.65 | |||||
EV-to-FCF | -2.13 | |||||
Price-to-Net-Current-Asset-Value | 5.06 | |||||
Price-to-Net-Cash | 5.45 | |||||
Earnings Yield (Greenblatt) % | -47.85 | |||||
FCF Yield % | -35 |